BACKGROUND: Frontotemporal dementia (FTD) is pathologically heterogeneous, sometimes revealing intraneuronal inclusions of neurofilaments. We therefore measured CSF neurofilament profiles in patients with FTD, patients with early onset Alzheimer's disease (EAD) and healthy control subjects to explore the discriminative potential of CSF neurofilaments compared with the existing CSF biomarkers amyloid-beta(1-42), tau and tau phosphorylated at threonine-181. METHODS: CSF levels of light chain, heavy chain and hyperphosphorylated heavy chain neurofilaments (NfL, t-NfH and P-NfH) were compared between 17 subjects with FTD, 20 with EAD and 25 cognitively healthy controls. RESULTS: A subgroup of FTD patients had remarkably high CSF levels of both NfL and NfH. The degree of NfH phosphorylation was increased in FTD compared to both other groups. The levels of CSF NfL were significantly higher in EAD compared to controls. CONCLUSION: Differences in CSF biomarker profiles might reflect differential involvement of neurofilaments and tau in FTD and EAD. The subgroup of FTD patients with high CSF neurofilament levels may have a different neuropathological substrate and future studies addressing this specific issue are needed. Copyright (c) 2007 S. Karger AG, Basel.
BACKGROUND: Frontotemporal dementia (FTD) is pathologically heterogeneous, sometimes revealing intraneuronal inclusions of neurofilaments. We therefore measured CSF neurofilament profiles in patients with FTD, patients with early onset Alzheimer's disease (EAD) and healthy control subjects to explore the discriminative potential of CSF neurofilaments compared with the existing CSF biomarkers amyloid-beta(1-42), tau and tau phosphorylated at threonine-181. METHODS:CSF levels of light chain, heavy chain and hyperphosphorylated heavy chain neurofilaments (NfL, t-NfH and P-NfH) were compared between 17 subjects with FTD, 20 with EAD and 25 cognitively healthy controls. RESULTS: A subgroup of FTDpatients had remarkably high CSF levels of both NfL and NfH. The degree of NfH phosphorylation was increased in FTD compared to both other groups. The levels of CSF NfL were significantly higher in EAD compared to controls. CONCLUSION: Differences in CSF biomarker profiles might reflect differential involvement of neurofilaments and tau in FTD and EAD. The subgroup of FTDpatients with high CSF neurofilament levels may have a different neuropathological substrate and future studies addressing this specific issue are needed. Copyright (c) 2007 S. Karger AG, Basel.
Authors: Claudia Ditzen; Ning Tang; Archana M Jastorff; Larysa Teplytska; Alexander Yassouridis; Giuseppina Maccarrone; Manfred Uhr; Thomas Bronisch; Christine A Miller; Florian Holsboer; Christoph W Turck Journal: Neuropsychopharmacology Date: 2011-12-14 Impact factor: 7.853
Authors: Davide Bruno; Nunzio Pomara; Jay Nierenberg; James C Ritchie; Michael W Lutz; Henrik Zetterberg; Kaj Blennow Journal: Exp Gerontol Date: 2011-10-01 Impact factor: 4.032
Authors: Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang Journal: Int J Alzheimers Dis Date: 2010-09-19
Authors: Joshua A Sonnen; Kathleen S Montine; Joseph F Quinn; Jeffrey A Kaye; John C S Breitner; Thomas J Montine Journal: Lancet Neurol Date: 2008-08 Impact factor: 44.182
Authors: Henrik Zetterberg; Tobias Skillbäck; Niklas Mattsson; John Q Trojanowski; Erik Portelius; Leslie M Shaw; Michael W Weiner; Kaj Blennow Journal: JAMA Neurol Date: 2016-01 Impact factor: 18.302